The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors.
 
Sapna Pradyuman Patel
Honoraria - Delcath Systems; Emory University
Consulting or Advisory Role - Bristol Myers Squibb; Castle Biosciences; Delcath Systems; immatics; Immunocore; Novartis; Pfizer; Replimune; TriSalus Life Sciences
Research Funding - Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - InxMed; TriSalus Life Sciences
 
Marie-Andree Forget
Consulting or Advisory Role - Proteios Technology
Patents, Royalties, Other Intellectual Property - License to Obsidian Therapeutics
 
Firas Y. Kreidieh
No Relationships to Disclose
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - 1200 Pharma (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); Leap Therapeutics (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Michael A. Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; NanoString Technologies; Novartis; Pfizer
Research Funding - ABM (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lead Pharma (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)
 
Rodabe Navroze Amaria
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Iovance Biotherapeutics; Novartis; Obsidian Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst); Obsidian Therapeutics (Inst)
 
Dan S. Gombos
Consulting or Advisory Role - Castle Biosciences
Travel, Accommodations, Expenses - Castle Biosciences
Other Relationship - 3T Ophthalmics; Aura Biosciences; Castle Biosciences
 
Chantale Bernatchez
Employment - Cell Therapy Manufacturing Center
Stock and Other Ownership Interests - Myst Therapeutics
Consulting or Advisory Role - Myst Therapeutics
Research Funding - Invectys (Inst); Iovance Biotherapeutics; Obsidian Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending - Human 4-1BB agonist antibodies and methods of use thereof; Patent pending - Methods for expansion of Tumor-Infiltrating Lymphocytes and use thereof; Patent pending on BTLA as a marker for better CD8 T cells for adoptive immunotherapy
Expert Testimony - Allogene Therapeutics